News
Trial sets up filings for Boehringer IPF drug nerandolimast
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandolimast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
